Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock
SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to… Read More


